DaVita Inc.
DVA
Rangering i aksjer
#1791
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Aksjekurs
$187.20
Sist synkronisert: 2026-10-19
Markedsverdi
$11.94B
Endring (1 dag)
0.21%
Endring (1 år)
46.19%
Land
US
Handel DaVita Inc. (DVA)
Kategori
Healthcare
P/E-forhold for DaVita Inc. (DVA)
P/E-forhold per October 2026 TTM: 15.54
Ifølge DaVita Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 15.54. Ved slutten av 2024 hadde selskapet en P/E på 13.57.
P/E-forholdshistorikk for DaVita Inc. fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 15.54 | 15.69% |
| 2025 | 13.43 | -1.10% |
| 2024 | 13.57 | -1.30% |
| 2023 | 13.75 | 11.00% |
| 2022 | 12.39 | 1.28% |
| 2021 | 12.23 | -32.70% |
| 2020 | 18.18 | 28.28% |
| 2019 | 14.17 | -74.30% |
| 2018 | 55.14 | 168.49% |
| 2017 | 20.54 | 39.58% |
| 2016 | 14.71 | -73.13% |
| 2015 | 54.76 | 146.24% |
| 2014 | 22.24 | 5.88% |
| 2013 | 21.00 | 6.08% |
| 2012 | 19.80 | 31.89% |
| 2011 | 15.01 | -13.66% |
| 2010 | 17.39 | 20.76% |
| 2009 | 14.40 | 3.35% |
| 2008 | 13.93 | -10.87% |
| 2007 | 15.63 | -23.10% |
| 2006 | 20.33 | -8.92% |
| 2005 | 22.32 | 27.09% |
| 2004 | 17.56 | 25.84% |
| 2003 | 13.95 | 23.89% |
| 2002 | 11.26 | -24.48% |
| 2001 | 14.92 | -85.60% |
| 2000 | 103.60 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 15.70 | 1.06% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -33.08% |
US
|
|
| 32.07 | 106.40% |
SA
|
|
| 20.00 | 28.72% |
BR
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.